Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03980041 |
|
Recruitment Status :
Completed
First Posted : June 10, 2019
Last Update Posted : November 25, 2022
|
Sponsor:
Infinity Pharmaceuticals, Inc.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | November 30, 2020 |
| Actual Study Completion Date : | November 15, 2022 |